Médecine

Paramédical

Autres domaines


S'abonner

Psoriasis, hepatitis B, and the tumor necrosis factor-alpha inhibitory agents: A review and recommendations for management - 14/11/12

Doi : 10.1016/j.jaad.2012.04.036 
Amanda Abramson, MD a, Alan Menter, MD a, Robert Perrillo, MD b,
a Division of Dermatology, Baylor University Medical Center, Dallas, Texas 
b Hepatology Division, Baylor University Medical Center, Dallas, Texas 

Correspondence to: Robert Perrillo, MD, Sammons Cancer Center, 3410 Worth St, Dallas 75246.

Abstract

Background

Tumor necrosis factor inhibitory agents are currently considered to be contraindicated in psoriatic patients with hepatitis B.

Objective

We aim to provide guidance to dermatologists on the use of tumor necrosis factor inhibitor therapy in these patients.

Methods

The current literature was reviewed regarding the use of tumor necrosis factor-alpha inhibitory agents (etanercept, adalimumab, and infliximab) in psoriatic patients with particular reference to hepatitis B infection.

Results

Tumor necrosis factor-alpha inhibitor therapy may result in reactivated hepatitis B in hepatitis B surface antigen-positive patients with psoriasis. This also occurs, although less frequently in patients with an isolated positive hepatitis B core antibody. Thus, all psoriasis patients should be screened for hepatitis B surface antigen plus hepatitis B core antibody prior to the initiation of tumor necrosis factor-alpha inhibitor therapy. Infliximab has been associated with more reactivation cases than the other 2 agents and fatalities have been reported with this agent. Evidence is presented that the risk of reactivation can be greatly minimized or eliminated by early or pre-emptive antiviral therapy.

Limitations

The data is largely based on small case series that are retrospective in nature.

Conclusions

Hepatitis B screening is essential prior to the initiation of tumor necrosis factor-alpha inhibitor therapy. Psoriatic patients found to be hepatitis B surface antigen or hepatitis B core antibody-positive should be referred to an appropriate specialist for evaluation and therapy. This would allow for the safe use of tumor necrosis factor-alpha inhibitors in psoriatic patients despite recently published guidelines to the contrary.

Le texte complet de cet article est disponible en PDF.

Key words : chronic hepatitis B, hepatitis B virus, liver function tests, psoriasis, tumor necrosis factor-alpha inhibitor

Abbreviations used : Anti-HBc, Anti-HBs, ALT, HBcAg, HBeAg, HBsAg, HBV, INF, Th1, TNF


Plan


 Funding sources: None.
 Disclosure: Dr Menter served on the advisory board and was a consultant, investigator, and speaker for Abbott Labs, Amgen, and Centocor, receiving grants and honoraria; served on the advisory board and was an investigator and consultant for Cephalon and UCB, receiving grants and honoraria; was a consultant, investigator, and speaker for Warner Chilcott and Wyeth, receiving honoraria; served on the advisory board and was an investigator for Galderma and Genentech, receiving grants and honoraria; was a consultant and investigator for Allergan and Astellas, receiving grants and honoraria; was an investigator for Collagenex, CombinatoRx, Dow, Ferndale, Leo, Medicis, Photocure, Pierre Fabre, 3M Pharmaceuticals, and XOMA, receiving grants; and was an investigator for Connetics, receiving grants and honorarium. Dr Perrillo currently serves on the hepatitis B advisory board of Roche Pharmaceuticals and is on the speaker’s bureau for Gilead Sciences and Bristol Myers Squibb. He has in the past received grant support from Bristol Myers Squibb and Roche Pharmaceuticals. He is the current Chair of the American Association for the Study of Liver Diseases Hepatitis B Special Interest Group. Dr Abramson has no conflicts of interest to declare.
 Reprints not available from the authors.


© 2012  American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 67 - N° 6

P. 1349-1361 - décembre 2012 Retour au numéro
Article précédent Article précédent
  • Stewart-Treves syndrome: Pathogenesis and management
  • Amit Sharma, Robert A. Schwartz
| Article suivant Article suivant
  • Collodion baby: An update with a focus on practical management
  • Renata Prado, Lixia Z. Ellis, Ryan Gamble, Tracy Funk, Harvey Alan Arbuckle, Anna L. Bruckner

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

;

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.